ARGENT cell-signaling regulation technology
ARIAD’s proprietary portfolio of cell-signaling regulation technologies includes the ARGENT signaling and transcription technologies. Our ARGENT technologies allow intracellular processes to be controlled with small molecules, which may be useful in the development of therapeutic vaccines and gene and cell therapy products, and which provide versatile tools for applications in cell biology, functional genomics and drug-discovery research, including three-hybrid screening approaches to discover and characterize targets and lead molecules.
We distribute our ARGENT technologies at no cost to academic investigators in the form of our Regulation Kits. We have entered into more than 1,500 material transfer agreements with more than 500 different institutions in 33 countries for the use of this technology in diverse areas of research, and more than 350 scientific papers describing their use have been published. In addition, we have licensed the ARGENT technology to several pharmaceutical and biotechnology companies for research and development and/or commercial purposes.
For more information, please refer to the Regulation Kits section of our website.
NF-κB cell-signaling technology
ARIAD has an exclusive license to pioneering technology and patents related to methods of treating human disease through modulation of the cell-signaling of a protein called NF-κB, and the discovery and development of drugs to regulate NF-κB cell-signaling activity. NF-κB can be generally thought of as a "biological switch" that can be turned off using these treatment methods to treat disorders such as inflammation, cancer, sepsis and osteoporosis.
We permit broad use of our NF-κB intellectual property at no cost by investigators at academic and not-for-profit institutions to conduct non-commercial research. Our goal is to license our NF-κB technology to pharmaceutical and biotechnology companies conducting research on the discovery of drugs that modulate NF-κB cell signaling and/or marketing such drugs.
One of our NF-κB patents is the subject of two outstanding lawsuits and a proceeding before the United States Patent and Trademark Office. For updated information about these proceedings, see our most recent filings with the Securities and Exchange Commission (including reports on Forms 8-K, 10-K, and 10-Q).
For more information about partnering and licensing opportunities with ARIAD, please contact Raymond T. Keane, Esq. at raymond.keane@ariad.com or (617) 494-0400.